Edition:
United States

Retrophin Inc (RTRX.O)

RTRX.O on Consolidated Issue listed on NASDAQ Global Market

23.93USD
14 Dec 2018
Change (% chg)

$-0.79 (-3.20%)
Prev Close
$24.72
Open
$24.52
Day's High
$25.21
Day's Low
$23.81
Volume
318,731
Avg. Vol
366,870
52-wk High
$33.00
52-wk Low
$20.09

Latest Key Developments (Source: Significant Developments)

Retrophin Reports Q3 Loss Per Share $1.34
Thursday, 1 Nov 2018 04:01pm EDT 

Nov 1 (Reuters) - Retrophin Inc ::RETROPHIN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.34.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.68.Q3 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $478.8 MILLION..QTRLY TOTAL NET PRODUCT SALES $40.7 MILLION VERSUS $40.3 MILLION.  Full Article

Retrophin Inc Files For Potential Mixed Shelf Offering; Size Not Disclosed
Tuesday, 4 Sep 2018 06:29pm EDT 

Sept 4 (Reuters) - Retrophin Inc ::RETROPHIN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING.  Full Article

Retrophin Announces Proposed Convertible Senior Notes Offering
Tuesday, 4 Sep 2018 04:06pm EDT 

Sept 4 (Reuters) - Retrophin Inc ::RETROPHIN ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING.RETROPHIN INC - INTENTION TO OFFER $200 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025.RETROPHIN - INTENDS TO USE PORTION OF NET PROCEEDS FROM OFFERING TO REPURCHASE PORTION OF OUTSTANDING 4.50% SENIOR CONVERTIBLE NOTES DUE 2019 FOR CASH.  Full Article

Retrophin Inc Q4 Loss Per Share $0.45
Tuesday, 27 Feb 2018 04:01pm EST 

Feb 27 (Reuters) - Retrophin Inc ::RETROPHIN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.45.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.07.QTRLY TOTAL NET PRODUCT SALES $42.2 MILLION VERSUS $37.3 MILLION.  Full Article

Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Retrophin Inc ::RETROPHIN PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK.‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​.‍COMPANY EXPECTS NET PRODUCT SALES FOR Q4 OF 2017 TO BE APPROXIMATELY $42 MILLION​.‍COMPANY EXPECTS A NEW DRUG APPLICATION FILING IN 2018 FOR ITS NEW FORMULATION OF THIOLA FOR TREATMENT OF CYSTINURIA.  Full Article

Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma
Friday, 5 Jan 2018 09:05am EST 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING.RETROPHIN SAYS IF CO EXERCISES OPTION TO BUY CENSA, COMPANY WILL HAVE TO PAY $65 MILLION IN UPFRONT CONSIDERATION.RETROPHIN - ‍AGREED TO FUND CERTAIN DEVELOPMENT ACTIVITIES OF CENSA'S CNSA-001 PROGRAM IN AMOUNT EXPECTED TO BE ABOUT $16 MILLION THROUGH PROOF OF CONCEPT​.RETROPHIN - ALSO ‍HAS RIGHT TO ACQUIRE CENSA ON TERMS AND SUBJECT TO CONDITIONS SET FORTH IN A SEPARATE AGREEMENT AND PLAN OF MERGER​.  Full Article

Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU).RETROPHIN INC - ‍UNDER DEAL TERMS , CO IS MAKING A $10 MILLION UPFRONT PAYMENT TO CENSA AND WILL PROVIDE FUNDING FOR DEVELOPMENT OF CNSA-001 IN PKU​.RETROPHIN - UNDER DEAL TERMS, ‍CENSA WILL RUN DEVELOPMENT PROGRAM FOR CNSA-001​, WHICH WILL BE CONDUCTED UNDER OVERSIGHT OF A JOINT STEERING COMMITTEE.  Full Article

Retrophin reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:21pm EST 

Nov 7 (Reuters) - Retrophin Inc :Retrophin reports third quarter 2017 financial results.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.46.Q3 adjusted non-GAAP earnings per share $0.15.  Full Article

Retrophin reports Q2 loss per share $0.34
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Retrophin Inc :Retrophin reports second quarter 2017 financial results.Q2 loss per share $0.34.Q2 revenue $39 million versus I/B/E/S view $37.4 million.Q2 adjusted non-gaap earnings per share $0.03.Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Protocol design for pivotal phase 3 trial of sparsentan in fsgs complete.Retrophin Inc - company reiterates its full-year 2017 guidance of $150.0 to $160.0 million in net product sales.  Full Article

Retrophin commences patient dosing in international, registrational phase 3 trial of RE-024 in PKAN
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Retrophin Inc :Retrophin commences patient dosing in international, registrational phase 3 trial of re-024 in pkan.Retrophin inc -announced that first patient has been dosed in fort study registrational phase 3 clinical trial assessing safety and efficacy of re-024.  Full Article